Otsuka Precision Health (OPH) and Click Therapeutics (Click) have commercially launched Rejoyn, a digital treatment designed to reduce the symptoms of depression.
Rejoyn offers brain exercises for six weeks to help target and adjust the neural connections essential for processing the emotions that reduce symptoms of depression.
Patients can obtain a prescription for Rejoyn from their current provider or another provider through a virtual consultation from Wheel Health.
OPH is commercialising Rejoyn through BlinkRx as its exclusive pharmacy provider, which will digitally dispense access codes for Rejoyn to prescribed patients.
The prescribed patients can download the Rejoyn mobile application and can use the application at a place and time of their choice.
Rejoyn’s fully digital prescribing and dispensing pathway can remove friction and enhance accessibility to facilitate a better patient experience, said OPH.
Otsuka Precision Health president Sanket Shah said: “We are proud to bring Rejoyn, the first-and-only FDA-cleared digital treatment for MDD symptoms, to market with transparent pricing that is affordable to most.
“This milestone has been over five years in the making and reflects the dedication, care, and evidence-based rigour with which we are developing digital treatments before putting them in the hands of patients.”
Rejoyn offers cognitive emotional brain training exercises, known as Emotional Faces Memory Task (EFMT), which enables the brain’s natural ability to change (neuroplasticity).
It also offers short skills-based therapy lessons based on Cognitive Behavioural Therapy (CBT) that provides the users with strategies and tools to manage depression.
In March 2024, the US Food and Drug Administration (FDA) approved Rejoyn as an adjunct to clinician-managed outpatient care, to treat major depressive disorder (MDD) in adults.
The US health regulator approved Rejoyn based on results from the Mirai study, a 13-week double-blinded, randomized, controlled trial of 386 participants, aged 22 to 64 years.
In the study, treatment with Rejoyn reduced depression symptoms and showed an improvement in the severity of depression symptoms from baseline.
The improvement was consistent across multiple patient and clinician-reported scales.
Otsuka Pharmaceutical development and commercialisation executive vice president and chief medical officer John Kraus said: “We all know someone with depression and the challenges in their treatment journey. There is no one-size-fits-all approach, which is why people continue to seek new options.
“We’re excited that MDD patients and their healthcare providers now have a new treatment option that works alongside medication – with no related side effects or drug-interaction concerns.”
